Analysis of the immune responses in chimpanzees infected with HIV type 1 isolates

AIDS Research and Human Retroviruses

Volumn 24, Issue 4, 2008, Pages 573-586

  Juompan, Laure Y ^a,b   Hutchinson, Karen ^c   Montefiori, David C ^d   Nidtha, Soumya ^a,e   Villinger, François ^a   Novembre, Francis J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e TransMed Partners LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL ACTIVITY; CHIMPANZEE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; VIREMIA; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; NEUTRALIZATION TESTS; PAN TROGLODYTES; RECEPTORS, CYTOKINE;

EID: 42449092899     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0182     Document Type: Article

References (62)

1. Gougeon ML, Lecoeur H, Boudet F, Ledru E, Marzabal S, Boullier S, Roue R, Nagata S, and Heeney J: Lack of chronic immune activation in HIV-infected chimpanzees correlates with the resistance of T cells to Fas/Apo-1 (CD95)-induced apoptosis and preservation of a T helper 1 phenotype. J Immunol 1997;158:2964-2976.
2. Kestens L, Vingerhoets J, Peeters M, Vanham G, Vereecken C, Penne G, Niphuis H, van Eerd P, van der Groen G, Gigase P, et al.: Phenotypic and functional parameters of cellular immunity in a chimpanzee with a naturally acquired simian immunodeficiency virus infection. J Infect Dis 1995;172:957-963.
3. Novembre FJ, Saucier M, Anderson DC, Klumpp SA, O'Neil SP, Brown CR 2nd, Hart CE, Guenthner PC, Swenson RB, and McClure HM: Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1. J Virol 1997;71:4086-4091.
4. O'Neil SP, Novembre FJ, Hill AB, Suwyn C, Hart CE, Evans-Strickfaden T, Anderson DC, deRosayro J, Herndon JG, Saucier M, and McClure HM: Progressive infection in a subset of HIV-1-positive chimpanzees. J Infect Dis 2000;182:1051-1062.
5. Novembre FJ, de Rosayro J, Nidtha S, O'Neil SP, Gibson TR, Evans-Strickfaden T, Hart CE, and McClure HM: Rapid CD4(+) T-cell loss induced by human immunodeficiency virus type 1(NC) in uninfected and previously infected chimpanzees. J Virol 2001;75:1533-1539.
6. Eichberg JW, Zarling JM, Alter HJ, Levy JA, Berman PW, Gregory T, Lasky LA, McClure J, Cobb KE, Moran PA, et al.: T-cell responses to human immunodeficiency virus (HIV) and its recombinant antigens in HIV-infected chimpanzees. J Virol 1987;61:3804-3808.
7. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, et al.: HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women [published erratum appears in Nat Med 1995;1(6):598]. Nat Med 1995;1:59-64.
8. Snyder-Cappione JE, Divekar AA, Maupin GM, Jin X, Demeter LM, and Mosmann TR: HIV-specific cytotoxic cell frequencies measured directly ex vivo by the Lysispot assay can be higher or lower than the frequencies of IFN-gamma-secreting cells: Anti-HIV cytotoxicity is not generally impaired relative to other chronic virus responses. J Immunol 2006;176:2662-2668.
9. Zuniga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, Hernandez A, Sanchez H, Frahm N, Linde CH, Hewitt HS, Hildebrand W, Altfeld M, Allen TM, Walker BD, Korber BT, Leitner T, Sanchez J, and Brander C: Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 2006;80:3122-3125.
10. Zarling JM, Eichberg JW, Moran PA, McClure J, Sridhar P, and Hu SL: Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins. J Immunol 1987;139:988-990.
11. Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, Chattergoon M, Frost P, Javadian A, Williams WV, Refaeli Y, Ciccarelli RB, McCallus D, Coney L, and Weiner DB: Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med 1997;3:526-532.
12. Lubeck MD, Natuk R, Myagkikh M, Kalyan N, Aldrich K, Sinangil F, Alipanah S, Murthy SC, Chanda PK, Nigida SM, Jr., Markham PD, Zolla-Pazner S, Steimer K, Wade M, Reitz MS, Jr., Arthur LO, Mizutani S, Davis A, Hung PP, Gallo RC, Eichberg J, and Robert-Guroff M: Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 1997;3:651-658.
13. Santra S, Fultz PN, and Letvin NL: Virus-specific cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected chimpanzees. J Virol 1999;73:7065-7069.
14. Robert-Guroff M, Kaur H, Patterson LJ, Leno M, Conley AJ, McKenna PM, Markham PD, Richardson E, Aldrich K, Arora K, Murty L, Carter L, Zolla-Pazner S, and Sinangil F: Vaccine protection against a heterologous, non-syncytium- inducing, primary human immunodeficiency virus. J Virol 1998;72:10275-10280.
15. Balla-Jhagjhoorsingh SS, Koopman G, Mooij P, Haaksma TG, Teeuwsen VJ, Bontrop RE, and Heeney JL: Conserved CTL epitopes shared between HIV-infected human long-term survivors and chimpanzees. J Immunol 1999;162:2308-2314.
16. Villinger F, Brar SS, Brice GT, Chikkala NF, Novembre FJ, Mayne AE, Bucur S, Hillyer CD, and Ansari AA: Immune and hematopoietic parameters in HIV-1-infected chimpanzees during clinical progression toward AIDS. J Med Primatol 1997;26:11-18.
17. Francis DP, Feorino PM, Broderson JR, McClure HM, Getchell JP, McGrath CR, Swenson B, McDougal JS, Palmer EL, Harrison AK, et al.: Infection of chimpanzees with lymphadenopathy-associated virus. Lancet 1984;2:1276-1277.
18. Fultz PN, McClure HM, Swenson RB, McGrath CR, Brodie A, Getchell JP, Jensen FC, Anderson DC, Broderson JR, and Francis DP: Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: A potential model for acquired immunodeficiency syndrome. J Virol 1986;58:116-124.
19. Watanabe M, Ringler DJ, Fultz PN, MacKey JJ, Boyson JE, Levine CG, and Letvin NL: A chimpanzee-passaged human immunodeficiency virus isolate is cytopathic for chimpanzee cells but does not induce disease. J Virol 1991;65:3344-3348.
20. Guenthner PC and Hart CE: Quantitative, competitive PCR assay for HIV-1 using a microplate-based detection system. Biotechniques 1998;24:810-816.
21. Montefiori DC, Robinson WE Jr, Schuffman SS, and Mitchell WM: Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol 1988;26:231-235.
22. Hutchinson KL, Villinger F, Miranda ME, Ksiazek TG, Peters CJ and Rollin PE: Multiplex analysis of cytokines in the blood of cynomolgus macaques naturally infected with Ebola virus (Reston serotype). J Med Virol 2001;65:561-566.
23. Hu SL, Fultz PN, McClure HM, Eichberg JW, Thomas EK, Zarling J, Singhal MC, Kosowski SG, Swenson RB, Anderson DC, et al.: Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature 1987;328:721-723.
24. O'Neil SP AD, Rafferty JR, Suwyn C, Domingues HG, Pauley DR, Boisvert K, Novembre FJ, and McClure HM: Pathogenesis of progressive HIV-1 infection in chimpanzees. In: 22nd Annual Symposium on Nonhuman Primate Models for AIDS. (San Antonio T, ed.), J Med Primatol 2004, p. 322.
25. Mwaengo DM and Novembre FJ: Molecular cloning and characterization of viruses isolated from chimpanzees with pathogenic human immunodeficiency virus type 1 infections. J Virol 1998;72:8976-8987.
26. Jost S, Bernard MC, Kaiser L, Yerly S, Hirschel B, Samri A, Autran B, Goh LE, and Perrin L: A patient with HIV-1 superinfection. N Engl J Med 2002;347:731-736.
27. Allen TM and Altfeld M: HIV-1 superinfection. J Allergy Clin Immunol 2003;112:829-835; quiz 836.
28. Villinger F, Bucur S, Chikkala NF, Brar SS, Bostik P, Mayne AE, Adams J, Lee ME, Novembre FJ, Gately MK, Ansari AA, and Hillyer CD: In vitro and in vivo responses to interleukin 12 are maintained until the late SIV infection stage but lost during AIDS. AIDS Res Hum Retroviruses 2000;16:751-763.
29. De Rose R, Batten CJ, Smith MZ, Fernandez CS, Peut V, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Venturi V, Davenport MP, and Kent SJ: Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J Virol 2006;81:292-300.
30. Ellenberger D, Otten RA, Li B, Aidoo M, Rodriguez IV, Sariol CA, Martinez M, Monsour M, Wyatt L, Hudgens MG, Kraiselburd E, Moss B, Robinson H, Folks T, and Butera S: HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology 2006;352:216-225.
31. Juompan L, Zhou J, Montefiori DC, and Novembre FJ: Resistance to neutralizing antibody and expanded coreceptor usage are associated with human immunodeficiency virus type 1 isolates derived from chimpanzees with pathogenic infections. AIDS Res Hum Retroviruses 2001;17:1705-1714.
32. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD, Griffith TS, Green DR, and Schoenberger SP: CD4+ Tcell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005;434:88-93.
33. Kalams SA and Walker BD: The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998;188:2199-2204.
34. Sun JC, Williams MA, and Bevan MJ: CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 2004;5:927-933.
35. Soudeyns H and Pantaleo G: The moving target: Mechanisms of HIV persistence during primary infection. Immunol Today 1999;20:446-450.
36. Krowka JF, Stites DP, Jain S, Steimer KS, George-Nascimento C, Gyenes A, Barr PJ, Hollander H, Moss AR, Homsy JM, et al.: Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro. J Clin Invest 1989;83:1198-1203.
37. Berzofsky JA, Bensussan A, Cease KB, Bourge JF, Cheynier R, Lurhuma Z, Salaun JJ, Gallo RC, Shearer GM, and Zagury D: Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature 1988;334:706-708.
38. Knox KS, Day RB, Kohli LM, Hage CA, and Twigg HL 3rd: Functional impairment of CD4 T cells despite normalization of T cell number in HIV. Cell Immunol 2006;242:46-51.
39. Sirianni MC, Soddu S, Malorni W, Arancia G, Aiuti F, and Soddus S: Mechanism of defective natural killer cell activity in patients with AIDS is associated with defective distribution of tubulin. J Immunol 1988;140:2565-2568.
40. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, and Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815.
41. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, and Doms RW: A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-1158.
42. Pandrea I, Apetrei C, Gordon S, Barbercheck J, Dufour J, Bohm R, Sumpter B, Roques P, Marx PA, Hirsch VM, Kaur A, Lackner AA, Veazey RS, and Silvestri G: Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts. Blood 2007;109:1069-1076.
43. Reimann KA, Li JT, Veazey R, Halloran M, Park IW, Karlsson GB, Sodroski J, and Letvin NL: A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996;70:6922-6928.
44. Reimann KA, Li JT, Voss G, Lekutis C, Tenner-Racz K, Racz P, Lin W, Montefiori DC, Lee-Parritz DE, Lu Y, Collman RG, Sodroski J, and Letvin NL: An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J Virol 1996;70:3198-3206.
45. Amadori A, Zamarchi R, Ciminale V, Del Mistro A, Siervo S, Alberti A, Colombatti M, and Chieco-Bianchi L: HIV-1-specific B cell activation. A major constituent of spontaneous B cell activation during HIV-1 infection. J Immunol, 1989;145:2146-2152.
46. Janoff EN, Hardy WD, Smith PD, and Wahl SM: Humoral recall responses in HIV infection. Levels, specificity, and affinity of antigen-specific IgG. J Immunol 1991;147:2130-2135.
47. Fan J, Nishanian P, Breen EC, McDonald M, and Fahey JL: Cytokine gene expression in normal human lymphocytes in response to stimulation. Clin Diagn Lab Immunol 1998;5:335-340.
48. Fauci AS: Host factors and the pathogenesis of HIV-induced disease. Nature 1996;384:529-534.
49. Clerici M and Shearer GM: A TH1 → TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-111.
50. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, and Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia [see comments]. Science 1997;278:1447-1450.
51. Mollet L, Li TS, Samri A, Tournay C, Tubiana R, Calvez V, Debre P, Katlama C, and Autran B: Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load. The RESTIM and COMET Study Groups. J Immunol 2000;165:1692-1704.
52. Belz GT, Wodarz D, Diaz G, Nowak MA, and Doherty PC: Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice. J Virol 2002;76:12388-12393.
53. Shankar P, Russo M, Harnisch B, Patterson M, Skolnik P, and Lieberman J: Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. Blood 2000;96:3094-3101.
54. Xiao Y, Dong X, and Chen YH: Neutralizing antibodies mechanism of neutralization and protective activity against HIV-1. Immunol Res 2002;25:193-200.
55. Silverstein PS, Mackay GA, Mukherjee S, Li Z, Piatak M Jr, Lifson JD, Narayan O, and Kumar A: Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time. J Virol 2000;74:10489-10497.
56. McHeyzer-Williams LJ, Malherbe LP, and McHeyzer-Williams MG: Helper T cell-regulated B cell immunity. Curr Top Microbiol Immunol 2006;311:59-83.
57. Ferrari G, Ottinger J, Place C, Nigida SM Jr, Arthur LO, and Weinhold KJ: The impact of HIV-1 infection on phenotypic and functional parameters of cellular immunity in chimpanzees. AIDS Res Hum Retroviruses 1993;9:647-656.
58. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
59. Mackewicz CE, Barker E, Greco G, Reyes-Teran G, and Levy JA: Do beta-chemokines have clinical relevance in HIV infection? J Clin Invest 1997;100:921-930.
60. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Ngole EM, Bienvenue Y, Delaporte E, Brookfield JF, Sharp PM, Shaw GM, Peeters M, and Hahn BH: Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006;313:523-526.
61. Van Heuverswyn F, Li Y, Neel C, Bailes E, Keele BF, Liu W, Loul S, Butel C, Liegeois F, Bienvenue Y, Ngolle EM, Sharp PM, Shaw GM, Delaporte E, Hahn BH, and Peeters M: Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 2006;444:164.
62. Zhan X, Martin LN, Slobod KS, Coleclough C, Lockey TD, Brown SA, Stambas J, Bonsignori M, Sealy RE, Blanchard JL, and Hurwitz JL: Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 2005;23:5306-5320.